CD274 and neoplasm: The expression of PD-L1 in tumor cells is currently utilized as a biomarker to predict the response to anti-PD-L1/PD-1 therapies, although it is documented that some patients with high PD-L1 expression may experience worsened clinical outcomes and patients with low PD-L1 expression may show complete response [6].